H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $41 from $44 and keeps a Buy rating on the shares following the Q1 report
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance
- Bicara Therapeutics Reports Q1 2025 Financial Results
- Promising Clinical Progress and Strategic Expansion Drive Buy Rating for Bicara Therapeutics
- Promising Potential of Bicara Therapeutics’ Ficera: A Buy Rating Backed by Strong Clinical Data and Innovative Approach
- Bicara Therapeutics reports Q1 EPS (68c), consensus (40c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue